viewCollagen Solutions PLC

Collagen Solutions waiting on CE Mark for ChondroMimetic knee cartilage scaffold

Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage

knee physio
The award of a CE Mark for ChondroMimetic could come as early as the end of March
  • Specialises in regenerative medicines and biomaterials

  • Makes everything from heart valves to wound dressings

  • Award of CE Mark for ChondroMimetic next major inflection point

  • Asian and European distribution agreements already in place


What it does

As it name suggests, Collagen Solutions PLC (LON:COS) specialises in making regenerative medicines and biomaterials.

It uses collagen and/ or tissue – such as pericardium – to make everything from heart valves to bone grafts right through to wound dressings. It all depends on what the customer wants.

Collagen has another string to its bow though, in the shape of its lead product called ChondroMimetic.

ChondroMimetic is a minimally-invasive surgically placed scaffold which helps to repair knee cartilage.

Last February, results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage.


How it’s doing

Work on a CE Mark, which would signify that the product has passed safety, health and environmental protection requirements, began almost straight after those results came in.

Collagen had hoped to hear whether or not it had been successful by the end of March 2019, although with the process out of its hands, it recently admitted that the timing of any award is “uncertain”.

Currently, ChondroMimetic is not approved for sale in any market, but Collagen has been working hard behind the scenes so that it is ready for sale as soon as the CE Mark is awarded.

Most recently, it signed a licence and distribution agreement with Rajawali Medika which it will work with to obtain regulatory approval and launch the cartilage scaffold in Indonesia. There is the potential for this deal to include several other countries in South East Asia as well.

That agreement adds to similar deals it has already secured elsewhere in Asia and in Europe.


Revenues rise in first half

Away from ChondroMimetic, Collagen saw demand for its products surge in the first half of its financial year.

The AIM company won nine new contracts in the six months ended September 30 (H1 17: eight) and began to supply to sixteen new customers (H1 17: eight).

That helped to push revenue up by 13% year-on-year to £2.10mln (H1 17: £1.86mln). When adjusted for the loss of a key Korean customer, who is not expected to order again until next year, revenue grew by 55%.

The new contracts were typically higher value than those that had been signed in the past as well, narrowing the half-year pre-tax loss to £1.06mln (H1 17: £1.64mln).

At the end of the period, Collagen had £2.56mln of cash in the bank, although in January it secured a £1.54mln grant from the Scottish government.


What the boss is saying

Quick facts: Collagen Solutions PLC

Price: 3.55 GBX

Market: LSE
Market Cap: £15.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...



Collagen Solutions sees clear path to profitability as commercial...

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence talk Proactive London's Andrew Scott through the firm's results for the year ended 31 March 2019. Revenues were up 22% in the year at £4.5mln, while its loss narrowed by just under £500,000 to £1.22mln. The core...

on 11/7/19

3 min read